A Phase 2 interventional study of Tolvaptan in Polycystic Kidney, Autosomal Dominant, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 11th largest by enrollment, is the only one that started in 2005, is one of 7 in phase 2, and was the 1st registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2005.
This study's enrollment of 46 is close to the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2005, is one of 5 in phase 2, and was the 1st registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire pilot efficacy data in patients with autosomal dominant polycystic kidney disease (ADPKD).
Autosomal Dominant Polycystic Kidney Disease is a genetic disease classified by the formation of fluid-filled cysts in the kidneys. The accumulation of these cysts causes the kidneys to enlarge several times the normal size and leads to the eventual loss of renal function and ultimately results in renal failure in end-stage patients. This is a disease with life-threatening implications to those who have it, and their family members who may also be affected. Aside from early anti-hypertensive control and dietary protein restriction, which are presumed to offer a modest degree of protection, most surviving patients require renal replacement therapy (dialysis and transplant) and suffer from high morbidity and mortality.
A rationale for use of tolvaptan in these genetic disorders has been proven, in principle, through use of a variety of animal models. In these models, tolvaptan is effective in halting or reversing the progression of this renal disease.
The current study is being undertaken in order to evaluate whether tolvaptan, an oral vasopressin V2 receptor inhibitor, will maintain an adequate safety profile and show a potential clinical benefit by reducing total renal volume in the hopes of making an impact upon disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
Drug: Tolvaptan
Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
Drug: Tolvaptan
Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
Also known as: OPC-41061
Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion.
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in a study , whether or not it was considered drug-related by the study physician. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study drug treatment; or if the event was continuous from Baseline and was serious, study drug related, or resulted in death, discontinuation.
Time frame: AEs were recorded from screening (ICF was signed) until 7-Day follow-up
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose.
Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.
Time frame: Baseline to Month 36
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose.
Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
Time frame: Baseline to Month 24
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime.
Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
Time frame: Baseline to Month 24
Percent Change From Baseline in Renal Volume.
Total Kidney Volume (TKV) was assessed by the central magnetic resonance imaging (MRI) rater.
Time frame: Baseline to Month 36
Change From Pre-dose Baseline in Renal Function Estimated by Glomerular Filtration Rate (GFR).
GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.
Time frame: Baseline to Month 36
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose- Extension.
Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36, Extension Day 1, and Extension Month 12 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.
Time frame: Baseline to Months 2, 6, 12, 24, 36, Extension Day 1, Extension Month 12
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose- Extension.
Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
Time frame: Baseline to Month 24
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime- Extension.
Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
Time frame: Baseline to Month 24
Percent Change From Baseline in Renal Volume-Extension.
TKV was assessed by the central magnetic resonance imaging (MRI) rater.
Time frame: Baseline to Months 2, 12, 24, 36, Extension Day 1, Extension Month 12
Change From Pre-dose Baseline in Renal Function Estimated by GFR- Extension.
GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.
Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 12
Mean Change From Baseline in Systolic Blood Pressure (sBP) for Hypertension Assessment.
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
Time frame: Baseline to Month 36
Mean Change From Baseline in Diastolic Blood Pressure (dBP) for Hypertension Assessment.
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
Time frame: Baseline to Month 36
Mean Change From Baseline in Mean Arterial Pressure (MAP) for Hypertension Assessment.
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
Time frame: Baseline to Month 36
Mean Change From Baseline in sBP for Hypertension Assessment- Extension.
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12
Mean Change From Baseline in dBP for Hypertension Assessment- Extension.
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12
Mean Change From Baseline in MAP for Hypertension Assessment- Extension.
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12
Mean Change From Baseline in Patient-assessed Renal Pain Scale.
Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.
Time frame: Baseline to Month 36
Mean Change From Baseline in Patient-assessed Renal Pain Scale- Extension.
Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.
Time frame: Baseline to Months 2, 6, 12, 24, 36, Extension Day 1, Extension Month 12
Mean Change From Baseline in Abdominal Girth Measurement.
The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).
Time frame: Baseline to Month 36
Mean Change From Baseline in Abdominal Girth Measurement- Extension.
The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).
Time frame: Baseline to Extension Day 1, Extension Month 12
A phase 2, multi-center, open-label trial, to determine the safety, tolerability, and efficacy study of split-dose oral regimens of tolvaptan tablets in a range of 30 to 120 mg/d in autosomal dominant polycystic kidney disease (ADPKD) participants.
| Milestone | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Started | 22 | 24 |
| Completed | 18 | 21 |
| Not completed | 4 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Met withdrawal criteria | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 |
| Milestone | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Started | 17 | 18 |
| Completed | 17 | 18 |
| Not completed | 0 | 0 |
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in a study , whether or not it was considered drug-related by the study physician. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study drug treatment; or if the event was continuous from Baseline and was serious, study drug related, or resulted in death, discontinuation.
| participants | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Participants with serious TEAEs | 3 | 8 |
| Participants with severe TEAEs | 6 | 10 |
| Participants discontinued due to AEs | 3 | 1 |
Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.
| mOsm/kg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 21, 22) | -274.10 ± 223.14 | -228.00 ± 238.19 |
| Month 6 (N= 19, 23) | -288.42 ± 219.55 | -263.78 ± 221.05 |
| Month 12 (N= 17, 21) | -227.29 ± 226.63 | -178.43 ± 228.43 |
| Month 24 (N= 18, 20) | -170.17 ± 272.21 | -189.75 ± 229.33 |
| Month 36 (N= 18, 21) | -222.50 ± 229.91 | -208.90 ± 194.19 |
Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
| mOsm/kg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 21, 21) | -263.95 ± 220.40 | -298.71 ± 257.53 |
| Month 6 (N= 19, 23) | -321.78 ± 242.53 | -294.13 ± 215.95 |
| Month 12 (N= 16, 20) | -288.20 ± 216.85 | -234.65 ± 238.82 |
| Month 24 (N= 1, 7) | -405.00 ± NA | -227.14 ± 334.13 |
Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
| mOsm/kg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 21, 22) | -275.00 ± 219.37 | -291.09 ± 194.88 |
| Month 6 (N= 19, 23) | -327.41 ± 217.15 | -301.83 ± 210.55 |
| Month 12 (16, 18) | -283.21 ± 230.81 | -245.83 ± 234.46 |
| Month 24 (N= 1, 7) | -263.00 ± NA | -246.00 ± 208.50 |
Total Kidney Volume (TKV) was assessed by the central magnetic resonance imaging (MRI) rater.
| Percentage change per month | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 21, 24) | -1.0 ± 5.2 | -1.3 ± 5.3 |
| Month 12 (N= 18, 22) | 0.3 ± 6.0 | 2.4 ± 6.6 |
| Month 24 (N= 18, 21) | 4.6 ± 8.4 | 1.0 ± 8.3 |
| Month 36 (N= 18, 20) | 9.9 ± 11.8 | 5.3 ± 10.0 |
GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.
| dL/mg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 22, 24) | -0.09 ± 0.11 | -0.05 ± 0.13 |
| Month 6 (N= 19, 21) | -0.03 ± 0.10 | -0.01 ± 0.12 |
| Month 9 (N= 18, 23) | -0.01 ± 0.12 | -0.03 ± 0.13 |
| Month 12 (N= 17, 22) | -0.03 ± 0.11 | -0.01 ± 0.18 |
| Month 16 (N= 18, 21) | -0.06 ± 0.12 | -0.02 ± 0.12 |
| Month 20 (N= 18, 21) | -0.06 ± 0.10 | -0.03 ± 0.15 |
| Month 24 (N= 18, 20) | -0.04 ± 0.10 | -0.02 ± 0.13 |
| Month 28 (N= 18, 21) | -0.07 ± 0.10 | -0.02 ± 0.14 |
| Month 32 (N= 18, 21) | -0.09 ± 0.14 | -0.06 ± 0.12 |
| Month 36 (N= 18, 21) | -0.07 ± 0.11 | -0.06 ± 0.13 |
Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36, Extension Day 1, and Extension Month 12 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.
| mOsm/kg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 17) | -328.06 ± 207.05 | -176.88 ± 225.54 |
| Month 6 (N= 17, 18) | -270.94 ± 200.29 | -223.50 ± 211.61 |
| Month 12 (N= 16, 17) | -234.56 ± 232.01 | -155.65 ± 242.53 |
| Month 24 (N= 17, 17) | -164.06 ± 279.32 | -160.06 ± 196.50 |
| Month 36 (N= 17, 18) | -234.71 ± 230.90 | -196.33 ± 175.23 |
| Extension Day 1 (N= 17, 17) | -54.59 ± 236.96 | -157.18 ± 229.19 |
| Extension Month 12 (N= 17, 18) | -115.59 ± 278.19 | -202.44 ± 227.92 |
Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
| mOsm/kg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 17) | -281.63 ± 235.90 | -254.82 ± 217.14 |
| Month 6 (N= 17, 18) | -305.25 ± 223.90 | -261.61 ± 201.49 |
| Month 12 (N= 16, 16) | -288.20 ± 216.85 | -190.69 ± 201.16 |
| Month 24 (N= 1, 6) | -405.00 ± NA | -120.50 ± 196.05 |
Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.
| mOsm/kg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 17) | -322.27 ± 207.32 | -258.88 ± 174.51 |
| Month 6 (N= 17, 18) | -309.73 ± 225.40 | -264.50 ± 180.12 |
| Month 12 (16, 15) | -283.21 ± 230.81 | -206.00 ± 200.36 |
| Month 24 (N= 1, 6) | -263.00 ± NA | -187.50 ± 153.04 |
TKV was assessed by the central magnetic resonance imaging (MRI) rater.
| Percentage change per month | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | -1.3 ± 5.4 | -1.4 ± 3.9 |
| Month 12 (N= 17, 18) | -0.7 ± 4.5 | 1.9 ± 5.7 |
| Month 24 (N= 17, 18) | 3.2 ± 6.0 | 0.2 ± 7.2 |
| Month 36 (N= 17, 18) | 7.9 ± 8.7 | 3.8 ± 7.4 |
| Extension Day 1 (N= 17, 18) | 14.1 ± 10.5 | 8.4 ± 7.9 |
| Extension Month 12 (N= 17, 18) | 15.7 ± 12.7 | 10.7 ± 10.4 |
GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.
| dL/mg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | -0.09 ± 0.11 | -0.04 ± 0.15 |
| Month 6 (N= 17, 16) | -0.03 ± 0.11 | -0.00 ± 0.13 |
| Month 9 (N= 16, 18) | -0.01 ± 0.11 | -0.01 ± 0.14 |
| Month 12 (N= 16, 17) | -0.03 ± 0.12 | -0.00 ± 0.21 |
| Month 16 (N= 17, 16) | -0.06 ± 0.12 | -0.01 ± 0.13 |
| Month 20 (N= 17, 18) | -0.06 ± 0.10 | -0.02 ± 0.16 |
| Month 24 (N= 17, 17) | -0.04 ± 0.11 | -0.02 ± 0.14 |
| Month 28 (N= 17, 18) | -0.06 ± 0.10 | -0.02 ± 0.14 |
| Month 32 (N= 17, 18) | -0.09 ± 0.14 | -0.05 ± 0.12 |
| Month 36 (N= 17, 18) | -0.07 ± 0.11 | -0.05 ± 0.14 |
| Extension Day 1 (N= 17, 18) | -0.04 ± 0.13 | -0.01 ± 0.17 |
| Extension Month 12 (N= 17, 18) | -0.05 ± 0.17 | -0.04 ± 0.14 |
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
| mmHg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 22, 24) | -3.2 ± 12.6 | -3.0 ± 15.4 |
| Month 6 (N= 19, 23) | -3.6 ± 10.8 | -5.0 ± 12.4 |
| Month 9 (N= 18, 23) | -4.6 ± 12.5 | -3.5 ± 12.5 |
| Month 12 (N= 18, 23) | -8.0 ± 14.6 | -3.5 ± 14.2 |
| Month 16 (N= 18, 23) | -6.2 ± 14.2 | -2.9 ± 12.6 |
| Month 20 (N= 18, 21) | -7.9 ± 11.4 | -10.0 ± 16.4 |
| Month 24 (N= 18, 21) | -2.1 ± 18.4 | -0.1 ± 14.7 |
| Month 28 (N= 18, 21) | -4.7 ± 14.2 | -4.1 ± 17.1 |
| Month 32 (N= 18, 21) | -7.3 ± 10.9 | -7.2 ± 14.8 |
| Month 36 (N= 18, 21) | -0.2 ± 13.2 | -5.4 ± 17.6 |
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
| mmHg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 22, 24) | -4.0 ± 11.4 | -0.2 ± 9.8 |
| Month 6 (N= 19, 23) | -3.6 ± 8.2 | -2.5 ± 11.2 |
| Month 9 (N= 18, 23) | -4.8 ± 8.9 | -2.8 ± 11.4 |
| Month 12 (N= 17, 23) | -9.2 ± 12.6 | -1.1 ± 12.6 |
| Month 16 (N= 18, 23) | -5.6 ± 11.4 | -2.3 ± 10.7 |
| Month 20 (N= 18, 21) | -7.4 ± 9.8 | -5.6 ± 12.1 |
| Month 24 (N= 18, 21) | -3.1 ± 11.6 | -0.1 ± 12.4 |
| Month 28 (N= 18, 21) | -5.3 ± 10.6 | -2.2 ± 8.8 |
| Month 32 (N= 18, 21) | -4.6 ± 11.2 | -3.0 ± 10.9 |
| Month 36 (N= 18, 21) | -5.4 ± 10.0 | -4.0 ± 13.2 |
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
| mmHg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 22, 24) | -3.7 ± 10.5 | -1.0 ± 10.5 |
| Month 6 (N= 19, 23) | -3.6 ± 7.4 | -3.3 ± 11.1 |
| Month 9 (N= 18, 23) | -4.7 ± 9.2 | -3.0 ± 10.8 |
| Month 12 (N= 18, 23) | -12.0 ± 18.9 | -1.8 ± 12.1 |
| Month 16 (N= 18, 23) | -5.8 ± 11.0 | -2.5 ± 10.6 |
| Month 20 (N= 18, 21) | -7.6 ± 9.7 | -7.0 ± 12.3 |
| Month 24 (N= 18, 21) | -2.7 ± 13.0 | -0.1 ± 12.0 |
| Month 28 (N= 18, 21) | -5.2 ± 11.2 | -2.7 ± 10.1 |
| Month 32 (N= 18, 21) | -5.6 ± 10.0 | -4.3 ± 11.2 |
| Month 36 (N= 18, 21) | -3.8 ± 9.6 | -4.4 ± 13.8 |
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
| mmHg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | -1.6 ± 13.0 | -2.7 ± 15.0 |
| Month 6 (N= 17, 18) | -3.4 ± 11.4 | -5.6 ± 13.7 |
| Month 9 (N= 16, 18) | -4.1 ± 13.2 | -4.3 ± 13.7 |
| Month 12 (N= 17, 18) | -8.9 ± 14.5 | -3.3 ± 15.5 |
| Month 16 (N= 17, 18) | -6.5 ± 14.5 | -1.7 ± 13.9 |
| Month 20 (N= 17, 18) | -7.7 ± 11.7 | -9.3 ± 17.1 |
| Month 24 (N= 17, 18) | -1.8 ± 18.9 | 1.4 ± 15.2 |
| Month 28 (N= 17, 18) | -4.9 ± 14.6 | -3.4 ± 17.7 |
| Month 32 (N= 17, 18) | -7.6 ± 11.1 | -6.8 ± 16.0 |
| Month 36 (N= 17, 18) | -0.6 ± 13.5 | -5.4 ± 18.8 |
| Extension Day 1 (N= 17, 18) | -4.4 ± 11.8 | -5.1 ± 14.9 |
| Extension Month 4 (N= 17, 18) | -1.1 ± 16.1 | -8.7 ± 11.8 |
| Extension Month 8 (N= 17, 18) | 1.8 ± 13.1 | -7.3 ± 14.8 |
| Extension Month 12 (N= 17, 18) | -0.5 ± 13.5 | -7.1 ± 12.2 |
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
| mmHg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | -5.5 ± 12.4 | 0.3 ± 9.7 |
| Month 6 (N= 17, 18) | -4.5 ± 8.2 | -2.4 ± 12.6 |
| Month 9 (N= 16, 18) | -5.3 ± 9.4 | -2.9 ± 11.8 |
| Month 12 (N= 16, 18) | -10.1 ± 12.4 | -1.9 ± 13.0 |
| Month 16 (N= 17, 18) | -6.9 ± 10.1 | -2.1 ± 12.0 |
| Month 20 (N= 17, 18) | -7.5 ± 10.0 | -6.1 ± 12.1 |
| Month 24 (N= 17, 18) | -3.9 ± 11.4 | -0.6 ± 12.7 |
| Month 28 (N= 17, 18) | -5.6 ± 10.8 | -2.9 ± 8.4 |
| Month 32 (N= 17, 18) | -5.4 ± 11.0 | -3.6 ± 11.4 |
| Month 36 (N= 17, 18) | -5.7 ± 10.2 | -4.8 ± 14.0 |
| Extension Day 1 (N= 17, 18) | -7.9 ± 7.3 | -4.0 ± 10.8 |
| Extension Month 4 (N= 17, 18) | -6.8 ± 10.6 | -6.1 ± 10.8 |
| Extension Month 8 (N= 17, 18) | -5.0 ± 7.9 | -6.7 ± 12.7 |
| Extension Month 12 (N= 17, 18) | -6.0 ± 8.9 | -5.6 ± 11.7 |
The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).
| mmHg | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | -4.1 ± 11.6 | -0.6 ± 10.0 |
| Month 6 (N= 17, 18) | -4.2 ± 7.7 | -3.4 ± 12.5 |
| Month 9 (N= 16, 18) | -4.8 ± 9.8 | -3.4 ± 11.5 |
| Month 12 (N= 17, 18) | -13.1 ± 18.9 | -2.3 ± 12.9 |
| Month 16 (N= 17, 18) | -6.8 ± 10.4 | -1.9 ± 11.8 |
| Month 20 (N= 17, 18) | -7.5 ± 10.0 | -7.2 ± 12.8 |
| Month 24 (N= 17, 18) | -3.1 ± 13.2 | 0.1 ± 12.6 |
| Month 28 (N= 17, 18) | -5.5 ± 11.4 | -2.9 ± 10.2 |
| Month 32 (N= 17, 18) | -6.2 ± 10.0 | -4.6 ± 12.0 |
| Month 36 (N= 17, 18) | -4.1 ± 9.8 | -5.1 ± 14.8 |
| Extension Day 1 (N= 17, 18) | -6.8 ± 7.8 | -4.4 ± 11.0 |
| Extension Month 4 (N= 17, 18) | -5.1 ± 10.7 | -6.9 ± 10.1 |
| Extension Month 8 (N= 17, 18) | -2.8 ± 8.6 | -6.8 ± 12.1 |
| Extension Month 12 (N= 17, 18) | -4.2 ± 9.3 | -6.0 ± 10.9 |
Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.
| Units on a scale | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 22, 24) | 0.6 ± 3.1 | 0.0 ± 1.6 |
| Month 6 (N= 19, 23) | 0.4 ± 2.8 | -0.1 ± 1.7 |
| Month 12 (N= 18, 23) | 1.2 ± 3.3 | -0.1 ± 2.1 |
| Month 24 (N= 18, 21) | 0.2 ± 1.6 | 1.0 ± 3.3 |
| Month 36 (N= 18, 21) | 0.6 ± 2.3 | 0.5 ± 2.2 |
Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.
| Units on a scale | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | 0.9 ± 2.7 | 0.3 ± 1.3 |
| Month 6 (N=17, 18) | 0.8 ± 2.5 | -0.2 ± 1.9 |
| Month 12 (N= 17, 18) | 1.2 ± 3.4 | -0.3 ± 2.0 |
| Month 24 (N= 17, 18) | 0.2 ± 1.6 | 0.8 ± 3.3 |
| Month 36 (N= 17, 18) | 0.6 ± 2.3 | 0.5 ± 2.4 |
| Extension Day 1 (N= 17, 18) | -0.3 ± 0.6 | 0.8 ± 2.1 |
| Extension Month 12 (N= 17, 18) | -0.4 ± 1.3 | -0.6 ± 2.2 |
The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).
| cm | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 22, 24) | 0.6 ± 5.0 | -2.3 ± 6.1 |
| Month 6 (N= 18, 23) | 1.4 ± 6.5 | 0.5 ± 4.6 |
| Month 12 (N= 18, 23) | 1.3 ± 4.7 | -2.8 ± 11.5 |
| Month 24 (N= 17, 21) | 2.0 ± 7.4 | -0.6 ± 6.7 |
| Month 36 (N= 18, 21) | 3.1 ± 7.2 | 0.3 ± 7.3 |
The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).
| cm | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Month 2 (N= 17, 18) | -0.8 ± 3.9 | -2.8 ± 7.0 |
| Month 6 (N= 16, 18) | 0.3 ± 5.6 | 0.3 ± 5.1 |
| Month 12 (N= 17, 18) | 1.1 ± 4.8 | -3.5 ± 12.9 |
| Month 24 (N= 17, 21) | 2.0 ± 7.4 | -1.1 ± 7.1 |
| Month 36 (N= 17, 18) | 2.5 ± 6.9 | 0.1 ± 7.7 |
| Extension Day 1 (N= 17, 18) | 4.2 ± 7.2 | 2.9 ± 7.9 |
| Extension Month 12 (N= 17, 18) | 4.6 ± 9.5 | 1.6 ± 6.1 |
Collected over AEs were recorded from screening (ICF was signed) until 7-days of safety follow-up. Participants with AEs in multiple system organ classes were counted only once towards the total.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan 45+15 mg | — | 3/22 (13.6%) | 20/22 (90.9%) |
| Tolvaptan 60+30 mg | — | 8/24 (33.3%) | 23/24 (95.8%) |
| Event | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/22 | 2/24 |
| CholelithiasisHepatobiliary disorders | 1/22 | 0/24 |
| Pituitary tumor benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/22 | 0/24 |
| Renal painRenal and urinary disorders | 1/22 | 1/24 |
| TachycardiaCardiac disorders | 0/22 | 1/24 |
| Polycystic liver diseaseCongenital, familial and genetic disorders | 0/22 | 1/24 |
| Abdominal painGastrointestinal disorders | 0/22 | 1/24 |
| Epiploic appendagitisGastrointestinal disorders | 0/22 | 1/24 |
| Chest painGeneral disorders | 0/22 | 1/24 |
| PyelonephritisInfections and infestations | 0/22 | 1/24 |
| Event | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg |
|---|---|---|
| Renal painRenal and urinary disorders | 9/22 | 9/24 |
| DizzinessNervous system disorders | 6/22 | 3/24 |
| PolyuriaRenal and urinary disorders | 6/22 | 2/24 |
| Upper respiratory tract infectionInfections and infestations | 1/22 | 6/24 |
| Urinary tract infectionInfections and infestations | 1/22 | 6/24 |
| NocturiaRenal and urinary disorders | 5/22 | 2/24 |
| Abdominal painGastrointestinal disorders | 2/22 | 5/24 |
| FatigueGeneral disorders | 4/22 | 5/24 |
| ThirstGeneral disorders | 1/22 | 5/24 |
| Back painMusculoskeletal and connective tissue disorders | 4/22 | 3/24 |
| Age, Continuous(Years) | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg | Total |
|---|---|---|---|
| Mean | 39.3 ± 8.4 | 43.9 ± 7.8 | 41.7 ± 8.3 |
| Sex: Female, Male(Participants) | Tolvaptan 45+15 mg | Tolvaptan 60+30 mg | Total |
|---|---|---|---|
| Female | 16 | 18 | 34 |
| Male | 6 | 6 | 12 |
The record gives a start of Dec 2005, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 7 years 1 month after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →